Alerts will be sent to your verified email
Verify Email
ASTRAZEN
|
Astrazeneca Pharma I
|
Alembic Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
18.6 % | n/a | 6.1 % |
|
R&D as a % of Total Sales
|
0.0 | 8.0 % | 0.0 |
|
Financials
|
|||
|
5 yr Average ROE
|
17.42 % | 12.89 % | 17.74 % |
|
5yr average Equity Multiplier
|
1.99 | 1.39 | 1.76 |
|
5yr Average Asset Turnover Ratio
|
0.91 | 0.86 | 0.51 |
|
5yr Avg Net Profit Margin
|
9.65 % | 11.15 % | 22.76 % |
|
Price to Book
|
26.91 | 3.63 | 8.04 |
|
P/E
|
113.04 | 31.23 | 59.3 |
|
5yr Avg Cash Conversion Cycle
|
-6.33 Days | 9.46 Days | -54.68 Days |
|
Inventory Days
|
68.19 Days | 99.1 Days | 27.48 Days |
|
Days Receivable
|
35.81 Days | 66.32 Days | 54.07 Days |
|
Days Payable
|
187.52 Days | 164.9 Days | 148.48 Days |
|
5yr Average Interest Coverage Ratio
|
142.38 | 30.59 | 66.44 |
|
5yr Avg ROCE
|
23.84 % | 15.26 % | 18.34 % |
|
5yr Avg Operating Profit Margin
|
14.57 % | 17.29 % | 34.43 % |
|
5 yr average Debt to Equity
|
0.0 | 0.14 | 0.46 |
|
5yr CAGR Net Profit
|
4.4 % | -12.64 % | -0.19 % |
|
5yr Average Return on Assets
|
8.92 % | 9.32 % | 12.4 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 69.67 % | 54.83 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 16.93 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.06 % | 2.53 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.26 % | 4.04 % | 6.42 % |
|
Astrazeneca Pharma I
|
Alembic Pharma
|
Eris Lifesciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|